Vertex Pharmaceuticals (VRTX) Receivables (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Receivables of $2.0 billion for Q1 2026, up 10.58% year-over-year from $1.8 billion in Q1 2025, and down 2.76% quarter-over-quarter from $2.1 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Receivables (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Receivables history runs 18 years deep, the most recent figure standing at $2.0 billion for Q1 2026.
- In Q1 2026, Receivables rose 10.58% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (up 10.58% YoY), while the FY2025 annual figure was $2.1 billion, up 27.55% from the prior year.
- Receivables for Q1 2026 stood at $2.0 billion, down from $2.1 billion in the prior quarter.
- The five-year high for Receivables was $2.1 billion in Q4 2025, with the low at $1.3 billion in Q1 2022.
- The 5-year median for Receivables is $1.6 billion (2024), against an average of $1.7 billion.
- The sharpest annual moves came in 2022 and 2025: Receivables soared 43.45% in 2022, then gained 0.66% in 2025.
- Vertex Pharmaceuticals' Receivables stood at $1.4 billion in 2022, then rose by 8.4% to $1.6 billion in 2023, then increased by 2.94% to $1.6 billion in 2024, then grew by 27.55% to $2.1 billion in 2025, then declined by 2.76% to $2.0 billion in 2026.
- Business Quant data shows VRTX's Receivables at $2.0 billion in Q1 2026, $2.1 billion in Q4 2025, and $1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.13 Bn |
| Mar 31, 2026 | 2.00 Bn |
| Dec 31, 2025 | 2.05 Bn |
| Sep 30, 2025 | 1.95 Bn |
| Jun 30, 2025 | 1.89 Bn |
| Mar 31, 2025 | 1.81 Bn |
| Dec 31, 2024 | 1.61 Bn |
| Sep 30, 2024 | 1.75 Bn |
| Jun 30, 2024 | 1.66 Bn |
| Mar 31, 2024 | 1.79 Bn |
| Dec 31, 2023 | 1.56 Bn |
| Sep 30, 2023 | 1.54 Bn |
| Jun 30, 2023 | 1.56 Bn |
| Mar 31, 2023 | 1.55 Bn |
| Dec 31, 2022 | 1.44 Bn |
| Sep 30, 2022 | 1.39 Bn |
| Jun 30, 2022 | 1.33 Bn |
| Mar 31, 2022 | 1.29 Bn |
| Dec 31, 2021 | 1.14 Bn |
| Sep 30, 2021 | 1.10 Bn |